Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 20/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | HTR1A | P08908 | 2/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.51 |
| ▸ | HTR2A | P28223 | 2/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.51 |
| ▸ | HTR2B | P41595 | 2/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2936779 | 1.00 | REN (0.61) | RENCYP3A4HTR1AADRA1DHTR2A | |
| SCHEMBL2936199 | 1.00 | REN (0.61) | RENCYP3A4HTR1AADRA1DHTR2A | |
| SCHEMBL2932495 | 0.93 | REN (0.71) | RENCYP3A4HTR1AADRA1DHTR2A | |
| SCHEMBL2981166 | 0.93 | REN (0.71) | RENCYP3A4HTR1AADRA1DHTR2A | |
| SCHEMBL2932215 | 0.89 | REN (0.61) | RENCYP3A4HTR1AADRA1DHTR2A | |
| SCHEMBL2932461 | 0.87 | REN (0.59) | RENCYP3A4HTR1AADRA1DHTR2A | |
| SCHEMBL2937185 | 0.87 | REN (0.59) | RENCYP3A4HTR1AADRA1DHTR2A | |
| SCHEMBL2936669 | 0.86 | REN (0.53) | RENCYP3A4HTR1AADRA1DHTR2A | |
| SCHEMBL2930843 | 0.86 | REN (0.62) | RENCYP3A4HTR1AADRA1DHTR2A | |
| SCHEMBL2936160 | 0.85 | REN (0.70) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836163-B1 | PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN | NOVARTIS AG (CH) | 2010-09-22 | — | — | EP | disclosed |